Navigation Links
Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

HUNTINGTON BEACH, California and AMSTERDAM, December 12 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint(R)'s ability to predict response to neoadjuvant chemotherapy in breast cancer.

Dr. Laura van 't Veer, from the Netherlands Cancer Institute, presented the data at the 2008 San Antonio Breast Cancer Symposium (SABCS) during the session Molecular profiling for guiding therapeutic decisions. The study analyzed the association between the pathological complete response (pCR) rate and the results of the MammaPrint test.

"Physicians are increasingly supportive of MammaPrint in clinical practice because they believe it provides them with invaluable information for patient treatment planning. MammaPrint's ability to accurately determine high risk patient responsiveness to chemotherapy both confirm and speak to the confidence physicians express in this state-of-the-art genomic breast cancer test," commented Dr. Richard Bender, Chief Medical Officer of Agendia and a life-long practicing oncologist who made a career at the NCI, Kaiser Permanente and Quest Diagnostics.

Findings in the neoadjuvant setting support MammaPrint's predictive power for chemotherapy response, in addition to its previously demonstrated prognostic value for early stage disease. The achievement of pCR is a valuable indicator for long-term response in this clinical setting.

A consecutive series of 167 patients who received neoadjuvant chemotherapy for stage II or III breast cancer were analyzed to assess MammaPrint's potential predictive power. 20 percent of the 144 patients in the poor prognosis signature group achieved a pCR, whereas none of the patients with a good prognosis signature achieved a pCR. After a median follow-up of 25 months, 19 relapses were seen in the poor signature and none in the good signature group. These findings suggest tumors with a poor prognosis MammaPrint signature are sensitive to chemotherapy.

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis - those patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test result provides a doctor with a clear rationale to assess the benefit of adjuvant chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-certified service laboratory. All other breast cancer recurrence assays currently marketed have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information please visit

Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
2. DNA Test Predicts Harmful Effects of Cancer Drug
3. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
4. Simple Test Accurately Predicts Risk of Serious Jaundice in Newborns
5. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
6. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
7. Directors Forum: PEPFAR and the Global AIDS Response
8. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
9. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
10. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
11. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
Post Your Comments:
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... UTRECHT , Nederland, November 26, 2015 ... --> Een nieuwe aanpak combineert ... van gevorderde kanker. ... -->      (Photo: ... van het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... 29, 2015 , ... Key Housing, a top-rated corporate housing service for the ... apartment community: Epic. In showcasing this featured apartment community in San Jose, Key Housing ... market to efficiently find housing suitable to their needs by showcasing quality housing. , ...
(Date:11/28/2015)... ... ... 6:00 a.m. EST until 11:59 p.m. EST, customers will be racing the ... orders $80 or more to free gifts with purchases, there will be a new sale ... website for skin care and cosmetic needs, customers will save on already discounted prices. , ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... University of Toronto and the University of British Columbia suggested that laws requiring bicyclists ... The article explains that part of the reason for the controversial conclusion is that, ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, from ... dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. , ... prescription medications. In doing so, it could help to prevent potential overdose situations. ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ProSidebar: ... in Final Cut Pro X. With ProSidebar: Fasion, video editors can easily add ... ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop zones, lines, ...
Breaking Medicine News(10 mins):